GlassScriptPhysician profile
Ray Harvey Mclaughin
NPI 1720215049
$331,590.11
in general payments reported to CMS, 2019-2025
42 companies · $103K in 2025
The $103K reported for 2025 was more than what 98% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32K · 2020: $9,743 · 2021: $18K · 2022: $51K · 2023: $44K · 2024: $74K · 2025: $103K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $178K · Consulting Fee: $16K · Food and Beverage: $14K · Travel and Lodging: $13K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $178,144.50 |
| Consulting Fee | $15,682.00 |
| Food and Beverage | $13,611.80 |
| Travel and Lodging | $13,490.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $86,050.28 | 2019-2025 | |
| Amgen INC. | $67,946.51 | 2019-2025 | Evenity, Otezla, Tavneos |
| Genzyme Corporation | $59,407.10 | 2020-2025 | |
| Ucb, INC. | $52,903.78 | 2019-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $22,338.30 | 2019-2023 | Taltz, Olumiant, Mounjaro |
| Celgene Corporation | $16,459.54 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $13,169.78 | 2019-2020 | |
| Aurinia Pharma U.S., INC. | $3,115.42 | 2021-2024 | Lupkynis |
| Sobi, INC | $2,440.16 | 2025 | |
| Janssen Biotech, INC. | $2,419.78 | 2019-2025 | Tremfya, Simponi Aria |
| Glaxosmithkline, LLC. | $1,363.68 | 2019-2025 | Benlysta |
| Radius Health, INC. | $772.55 | 2020-2025 | Tymlos |
| Horizon Therapeutics Plc | $514.93 | 2019-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $435.30 | 2023-2025 | Saphnelo, Breztri |
| Pfizer INC. | $311.07 | 2019-2025 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ray Mclaughin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.